Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2025 on February 26, 2026, after U.S. market close, followed by a live conference call and webcast [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA®: an extended-release injectable for managing osteoarthritis knee pain [3] - iovera®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature application [3] - Pacira is advancing a pipeline of clinical-stage assets for musculoskeletal pain, with its leading candidate, PCRX-201, in Phase 2 clinical development for knee osteoarthritis [3]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

UroGen Pharma Conference Call Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Founded**: In Israel, addressing unmet needs in treating urothelial cancers - **Technology**: RTGel platform, a reverse thermal gel that allows sustained release of medications in the bladder [5][6] Core Products - **Commercial Assets**: - **Jelmyto**: Approved for low-grade upper tract urothelial carcinoma (6,000 patients in the U.S.) - **ZUSDURI**: Recently approved for low-grade intermediate-risk bladder cancer (60,000 patients in the U.S.) [7][8] Market Opportunity - **Patient Demographics**: - 60,000 newly diagnosed recurrent patients annually, with 68% having two or more recurrences [16] - 20,000 recurrent newly diagnosed patients, with a significant prevalent pool of low-grade intermediate-risk patients [16] - **Unmet Medical Need**: Historically, treatment was limited to surgical intervention (TURBT), leading to high recurrence rates [13][14] Product Launch and Performance - **ZUSDURI Launch**: - Initial revenue of $1.8 million, with October revenue reaching $4.5 million, indicating strong early performance [19] - Permanent J-code introduced in January, expected to accelerate uptake [36] - **Market Penetration**: - Estimated peak sales potential for ZUSDURI is over $1 billion, requiring only 20% market share to achieve this [37] Clinical Data and Feedback - **Efficacy**: - ZUSDURI demonstrated an 80% complete response rate, with 80% of those patients maintaining response at 12 months [25] - 90% of patients preferred ZUSDURI over TURBT based on patient-reported outcomes [25] - **Physician Feedback**: Positive reception from physicians, with many expressing enthusiasm for a non-surgical treatment option [22][25] Competitive Landscape - **Positioning**: UroGen believes ZUSDURI is the best treatment option due to its non-surgical nature and compelling clinical data [45] - **Market Growth**: The entry of additional treatments is seen as beneficial for overall market growth, with UroGen confident in its unique offering [44] Future Developments - **Next Generation Products**: - UGN-103 and UGN-104 are in development for broader applications in bladder cancer [48][51] - UGN-501, an oncolytic virus, is being explored for potential use in other cancers beyond urothelial [52] - **Long-term Strategy**: UroGen aims to diversify its portfolio while maintaining a focus on urothelial and specialty cancers [52] Financial Guidance - **Revenue Guidance**: UroGen is not providing specific revenue guidance for the upcoming year but is confident in continued growth based on current trends [39][63] Summary of Key Metrics - **ZUSDURI Market Size**: 60,000 patients, with a potential peak sales of $1.2 billion at 20% market share [37] - **Jelmyto Growth**: Continued single-digit growth, with increased physician engagement [55] This summary encapsulates the key points discussed during the UroGen Pharma conference call, highlighting the company's innovative approach to treating urothelial cancers and its strategic market positioning.

Core Insights - Eli Lilly has built a pre-launch inventory of its experimental oral weight-loss drug, orforglipron, valued at $1.5 billion ahead of an expected FDA decision in April [1] - This inventory has increased significantly from nearly $550 million reported last year, indicating strong preparation for a potential launch [1] - The company aims to have sufficient supply to launch the drug in multiple countries simultaneously if it receives U.S. approval [1] Company Developments - Eli Lilly's orforglipron has received a fast-track review voucher from the FDA, potentially reducing the review time to one to two months compared to the typical 10 to 12 months for new medicines [1] - The competitive landscape includes Danish rival Novo Nordisk, which recently launched its own weight-loss pill in the U.S., achieving over 26,000 prescriptions in the second week post-launch [1] Financial Implications - The pre-launch inventory is a strategic asset that reflects Eli Lilly's confidence in the drug's approval and market potential [1] - Such inventories are commonly included in financial statements to demonstrate the readiness of drug products prior to regulatory approval [1]

Core Viewpoint - An investigation has been announced regarding Inovio Pharmaceuticals, Inc. for potential violations of federal securities laws affecting investors [1] Group 1 - The Law Offices of Howard G. Smith are representing investors who may have suffered losses in Inovio Pharmaceuticals, Inc. [1] - Investors are encouraged to contact the law firm to discuss potential claims for recovering losses [1]

("Charming†or the "Company†) (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CHARMING MEDICAL LIMITED (MCTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PA...## Deadline Approaching: China Liberal Education Holdings Limited (CLEUF) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithBENSALEM, Pa.--([BUSINESS WIRE])--Law Offices of Howard G. Smith reminds investors of the upco ...

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Inovio Pharmaceuticals, Inc. for potential violations of federal securities laws, particularly concerning investor losses [1] Group 1 - The investigation is initiated on behalf of investors who may have lost money on Inovio Pharmaceuticals, Inc. [1] - The investigation follows the company's announcement made on August 8, 2024, after market hours [1]

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. announced that its subsidiaries have been selected for the continuation procurement of certain drugs under the national organized procurement program, which is expected to positively impact the company's sales and market share [1][2]. Group 1: Selected Drugs Information - The company’s subsidiaries participated in the national organized procurement for the continuation of drugs, with 11 products including Tamsulosin Hydrochloride Sustained-Release Capsules and Piperacillin Sodium and Tazobactam Sodium for Injection being selected [1]. - The procurement period for the selected drugs will last until December 31, 2028, starting from the implementation of the selection results [1]. Group 2: Financial Impact - The total sales revenue from the selected drugs for 2024 is projected to be 385.29 million, accounting for 5.91% of the company's total revenue of 6.52 billion for the same year [2]. - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million, representing 5.95% of the company's revenue of 4.98 billion [2]. - The selected drugs are expected to maintain stable or declining prices, which will help the company expand sales and enhance brand influence [2].

Leadership Change - Sanofi has announced the appointment of Belén Garijo as the new CEO, succeeding Paul Hudson, whose contract will not be renewed [1] - Garijo, currently the CEO of Merck KGaA, will assume her new role on April 29, 2026, after a five-year tenure at Merck KGaA [2] Financial Performance - Sanofi's vaccine revenue dropped by 5% in 2025, generating €7.9 billion compared to €8.3 billion in 2024, while overall net sales grew by 9.9% at constant exchange rates to reach €43.6 billion ($51.7 billion) [4] - The company is preparing for the loss of patent protection for Dupixent, which generated €14.7 billion last year [5] Challenges and Pipeline Issues - Sanofi is facing challenges in the US vaccine sector due to policy changes under the Trump administration, impacting immunization recommendations and new candidate approvals [3] - Recent pipeline disappointments include FDA rejections and failures in multiple sclerosis treatments, as well as mixed results for COPD candidates [6] Strategic Focus - Garijo's primary focus will be on enhancing the productivity, governance, and innovation capacity of Sanofi's R&D [7]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]